- Investing Ideas
- Australian Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Australian Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
2
0 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
2 companies
Mesoblast
Market Cap: AU$2.9b
Mesoblast Limited se dedica al desarrollo de productos de medicina regenerativa en Australia, Estados Unidos, Singapur y Suiza.
MSB
AU$2.23
7D
9.3%
1Y
-5.5%
Aroa Biosurgery
Market Cap: AU$195.4m
Aroa Biosurgery Limited desarrolla, fabrica y vende dispositivos médicos para la reparación de heridas y tejidos blandos mediante tecnología de matriz extracelular (MEC) en Estados Unidos y a escala internacional.
ARX
AU$0.56
7D
0%
1Y
-7.4%